PFIE-Emerg'IN partners with the AVITHRAPID consortium

PFIE-Emerg'IN partners with the AVITHRAPID consortium

The AVITHRAPID consortium has just been launched under the EU’s Horizon research programme. It is part of the EU’s Horizon research programme “Pandemic preparedness and response: broad spectrum antiviral therapeutics for infectious diseases with epidemic potential”. The project is coordinated by the German Fraunhofer-Gesellschaft and includes 18 leading research institutes from various European countries.

The objective of the project is to establish a pipeline of antiviral agents based on small molecules that can be widely used and rapidly developed in therapies against emerging infectious diseases.

The INRAE PFIE Experimental Unit, a member of EMERG'IN, is a partner in this project and is leading the work package dedicated to preclinical tests.

As part of this project, the consortium also intends to test a small molecule against the Zika virus in a clinical trial.

AVITHRAPID began in January 2024 for a period of 54 months.

Site web site:            https://avithrapid.eu/

Modification date : 04 April 2024 | Publication date : 03 April 2024 | Redactor : Emerg'IN